Ispecimen Inc. Stock Price, News & Analysis

iSpecimen Appoints Eric Langlois as Chief Revenue Officer

iSpecimen (Nasdaq: ISPC) has appointed Eric Langlois as Chief Revenue Officer, effective immediately. Langlois, previously Senior Vice President of Sales and Business Development, has played a pivotal role in achieving a remarkable 3,000% revenue growth during his tenure. He will manage a restructured commercial team to enhance alignment with customer needs and drive profitable growth. Under Langlois's leadership, iSpecimen has closed significant multi-million-dollar deals, contributing to record growth in Q4 2022. Langlois has extensive experience in pre-clinical research and biobanking, positioning him well to lead the company forward.

iSpecimen (Nasdaq: ISPC) has announced that CEO Tracy Curley will participate in the virtual Sequire Biotechnology Conference on February 2, 2023, at 5:00 p.m. ET. The company operates as an online marketplace connecting scientists with healthcare specimen providers for medical research. Interested attendees can register for the conference. iSpecimen utilizes proprietary cloud technology to facilitate searching for human biospecimens across a network of hospitals and labs. For more information about the conference or to arrange a meeting with management, attendees can reach out via email.

iSpecimen (Nasdaq: ISPC) announced that CEO Tracy Curley will participate in the Healthcare IT Virtual Conference, hosted by Maxim Group and M-Vest on January 25, 2023, at 8:30 a.m. ET. This conference aims to connect scientists with healthcare specimen providers for medical research. Attendees can register here. iSpecimen provides an online marketplace for biospecimens, facilitating research by connecting scientists with diverse healthcare providers.

iSpecimen Inc. (Nasdaq: ISPC) has appointed Tracy Curley as CEO, effective immediately, transitioning from her role as Interim CEO since September 2022. Curley expressed gratitude for the Board's confidence and highlighted the company's record revenue in Q4 2022. Andrew Ross, Chairman of the Board, commended Curley’s leadership and endorsed her permanent position. Following her appointment, a search for a new CFO will begin. iSpecimen connects scientists to biospecimens via an online marketplace, enhancing operational efficiency in medical research.

iSpecimen Inc. (Nasdaq: ISPC) has appointed Joseph J. Basile to its Board of Directors effective November 28, 2022, replacing Margaret H. Lawrence. Mr. Basile is a strategic advisor with extensive expertise in mergers, acquisitions, and corporate governance. His experience spans various sectors including life sciences and technology. Tracy Curley, Interim CEO, highlighted Mr. Basile's role in enhancing iSpecimen's M&A strategy. The company aims to leverage his skills to optimize stakeholder outcomes as it navigates significant operational transitions.

iSpecimen Inc. (Nasdaq: ISPC) reported Q3 2022 revenue of $2.6 million, with a record 88% ($2.26 million) from non-COVID sources, marking a 26% increase year-over-year. The company noted increased general and administrative expenses of about $2.2 million, resulting in a net loss of $3.1 million, compared to a $1.6 million loss in Q3 2021. Unique supplier and customer organizations increased to 217 and 480, respectively. iSpecimen’s cash reserves stood at approximately $20.7 million as of September 30, 2022. The company is pursuing multimillion-dollar initiatives and enhancing its Marketplace platform.

iSpecimen (Nasdaq: ISPC) has launched a new Open Feasibilities Dashboard on its iSpecimen Marketplace^®, enhancing transparency for supplier partners in the biospecimen procurement process. This feature allows suppliers to easily review potential research projects and flag high-priority specimens for quicker assessments. The dashboard aims to address existing limitations in the biospecimen sourcing process, ultimately facilitating more efficient collaboration between researchers and healthcare providers. This update supports the company's mission to advance medical research.

iSpecimen (Nasdaq: ISPC), an online marketplace connecting scientists with healthcare specimen providers, will announce its third quarter financial results for the period ending September 30, 2022, before market open on November 8, 2022. An audio webcast and conference call will be held on the same day at 8:30 a.m. Eastern Time, featuring remarks from Tracy Curley, Interim CEO and CFO. A replay will be available until November 22, 2022.

For more information, visit www.ispecimen.com.

iSpecimen (Nasdaq: ISPC) has launched its Marketplace Onsite program to enhance support for biospecimen provider partners. By embedding coordinators at select partner sites, the program streamlines the fulfillment of sample and data requests, thereby reducing strain on staff. The initiative aims to expand the provider network, increase access to high-demand biospecimens, and improve revenue growth. Interim CEO Tracy Curley emphasized the program's potential to address supplier constraints and facilitate vital medical research.